TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02497898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine-induced killer cells (CIK)
Description: Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
Study: NCT04839263

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FAST TRACK protocol
Description: Preoperative evaluation and information~Patient general health state optimization proposal prior to hospitalization:~Preoperative strategy:~* Hospitalization on surgery day~* No prolonged fasting~Perioperative strategy:~* Pain control based on limited systemic opioid therapy use~* Anti-nausea prophylaxis~* Anaesthesia via IV propofol / remifentanyl~* Bladder catheter removal postoperative~Postoperative strategy:~* Pain control using balanced analgesia~* Gum chewing~* Early oral refeeding and rapid mobilization~* Venflon removal 6 hours post-op
Study: NCT01976065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Antibiotic Paste
Description: USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Treatment
Description: Standard Treatment no use of study drug
Study: NCT03377504

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy and exercise program
Description: Routine physical therapy and exercise program including contrast baths, hot pack, TENS, desensitization, exercises and occupational therapy will be applied to all patients
Study: NCT00147901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCCam
Description: After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
Study: NCT02000739

Intervention type: GENETIC
Group type: OTHER
Intervention: Genetically Informed Therapy
Description: If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
Study: NCT02965222

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the time-lapse videography
Description: The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the time-lapse videography
Description: The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
Study: NCT01584180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's
Description: Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS Brain.Pad
Description: Passive external neck cooling with 1 EMCOOLS Brain.Pad
Study: NCT04465279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trifocal diffractive intraocular lens
Description: Trifocal IOL having foldable single-piece fully diffractive pupil dependent aspheric IOL. Which have been made of hydrophilic acrylic with an ultraviolet (UV) and blue light inhibitor. It has an optic diameter of 6.15 mm and an overall diameter of 10.75 mm; it has +3.5D additional power for near vision and +1.75 D additional power for intermediate vision, consisting of 26 diffractive steps.
Study: NCT04202926

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real coil
Description: active 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham coil
Description: sham 10Hz with a train of 3s on / 17s off, 50 trains, a total of 1500 pulses
Study: NCT00926510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language toolkit
Description: Simple toolkit of interactive things to stimulate language.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Safety counseling
Description: Smoke detector and general safety counseling
Study: NCT04396002

Intervention type: DIAGNOSTIC_TEST
Intervention: Life Space Questionnaire
Description: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.

Intervention type: DIAGNOSTIC_TEST
Intervention: Life Space Questionnaire
Description: This 9-item questionnaire is interested in finding out how much a person gets out and about and the spatial extent of the person's typical life space, i.e., what is the usual range of places in which the person engages in activities within the designated time frame.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Luminance Questionnaire
Description: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Low Luminance Questionnaire
Description: This 32-item questionnaire is interested in finding out problems that involve vision under different lighting conditions or feelings that people have about your vision under different lighting conditions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast sensitivity under dim illumination
Description: Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast sensitivity under dim illumination
Description: Participants will be presented with visual targets of different contrast under dim illumination and asked to report when they see the target.

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field under dim illumination (MAIA)
Description: Sensitivity in the central visual area will be assessed under dim illumination

Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field under dim illumination (MAIA)
Description: Sensitivity in the central visual area will be assessed under dim illumination

Intervention type: DIAGNOSTIC_TEST
Intervention: Macular Pigment Optical Density (MPOD)
Description: Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Macular Pigment Optical Density (MPOD)
Description: Participants will be asked to look at a fixation target and the density of their macular pigment will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dark Adaptation
Description: After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Dark Adaptation
Description: After adapting to a dark environment, participants will be exposed a bright flask of light. the time needed for them to recover their sensitivity will be measured.
Study: NCT03784690

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized intraoperative BP management
Description: In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP).~Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard intraoperative BP management
Description: Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.
Study: NCT05381298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Margin Elevation using resin composite
Description: After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep Margin Elevation using resin composite
Description: After completion of the root canal treatment of the offended tooth and comprehensive evaluation of the obtained treatment, the randomly allocated patients will undergo deep margin elevation procedure where rubber dam isolation will be accomplished Followed by proper matricing and wedging ) followed by selective enamel etching for 10 seconds then universal adhesive application following the manufacturer instructions followed by application of flowable resin composite for the first 1 mm and light cured for 20 seconds according to the manufacturer recommendations followed by application of packable bulk fill composite to elevate the margins and light cured following the manufacturer instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Crown Lengthening
Description: Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Crown Lengthening
Description: Participants in this group will undergo surgical crown lengthening in which an internal bevel incision will be done buccally and lingually followed by full thickness flap reflection using mucoperiosteal elevator, then interproximal bone removal will be done using end cutting bur to the planned position away from the margins by 3 mm. The flap will be displaced apically with apically positioned sutures. Postoperative instructions will be given to the patient aiming to control postsurgical complications including pain and swelling. Suture removal and assessment of the surgical site will be done after two weeks
Study: NCT01667913

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: 6 minutes walking test
Study: NCT02020122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: duloxetine 60mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: pregabalin 150mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: non active placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non active placebo
Study: NCT02713711

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: phototherapy
Description: Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: balneophototherapy
Description: Twelve sessions of both balneotherapy and phototherapy treatments.
Study: NCT00540787

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation, antiarrhythmic drugs
Description: Patients receive either treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation, antiarrhythmic drugs
Description: Patients receive either treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs
Description: Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ThermoCool Radiofrequency Catheter
Description: Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
Study: NCT03943589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: All subjects will receive imlifidase (Day 1) prior to standard care IVIg
Study: NCT03364348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ado-Trastuzumab Emtansine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ado-Trastuzumab Emtansine
Description: Given IV
Study: NCT02483286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICG
Description: Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.~The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.~Subjects are encouraged to practice study home exercise program at least twice weekly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MTG
Description: MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: XBG
Description: XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
Study: NCT04590170

Intervention type: BEHAVIORAL
Intervention: Post-intensive Care unit syndrome
Description: Post-intensive Care unit syndrome after an intensive care unit stay for the COVID19

Intervention type: OTHER
Intervention: Spatiotemporal measurements of walking
Description: Spatiotemporal measurements of walking in asymptomatic participants from the general population.
Study: NCT00574470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab, infliximab
Description: Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
Study: NCT01128998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 1. Name: Sorafenib~2. Dosage form: 200 mg / Tablet~3. Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: 1. Name:S-1~2. Dosage form: 20 mg or 25 mg / Capsule~3. Dosing schedule: 20-40 mg/m2 bid,po, 14 days on \& 7 days off
Study: NCT03997565

Intervention type: PROCEDURE
Intervention: TKR
Description: No intervention provided, but investigation of the ability to modulate motor performance during specific and functional tasks in subjects undergoing TKR compared with healthy subjects.
Study: NCT01842295

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Blood and sperm samples
Description: Blood and sperm samples will be done in each visit
Study: NCT04271943

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer Based Exercises
Description: For 8 weeks 3 days a week for 45 minutes See-ME Virtual Rehabilitation system with the physical therapist will perform cognitive and physical activity exercises

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercises
Description: For 8 weeks 3 days a week exercise bike with 5 min warm-up 35 min constant speed exercise 5 min cooling, a total of 45 min prescribed by the physiotherapist to the maximum heart rate will do aerobic exercise work. Cardiac values will also be monitored throughout the session
Study: NCT03710525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Own-Price Elasticity
Description: The price of vegetables will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-Price Elasticity
Description: The price of vegetables will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
Study: NCT04559581

Intervention type: DRUG
Intervention: Nintedanib
Description: Capsules
Study: NCT01170338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline 100 mg by mouth twice daily
Description: this is an active drug to help smoking cessation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: this is the placebo that will help us maintain a blinded study
Study: NCT03236441

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: Remote ischemic preconditioning

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-RIPC
Description: Control
Study: NCT03135535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avex Footbeat
Description: Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
Study: NCT02323646

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telapristone Acetate
Description: Telapristone acetate, vaginally, once daily for 18 weeks (Course 1) and repeated for an additional 18 weeks (Course 2) following the ODI.
Study: NCT02278133

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Study: NCT02025361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrarectal lidocaine gel
Description: intrarectal local anesthetic application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: periprostatic nerve blockade
Description: periprostatic local anesthetic application
Study: NCT04664725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide, Bupropion and SHR3680
Description: Single dose of oral administration of Repaglinide and Bupropion, Multiple dose of oral of SHR3680
Study: NCT02452632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral